{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:53:41Z","timestamp":1793199221415,"version":"4.5.0"},"reference-count":88,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":141,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["CA282041"],"award-info":[{"award-number":["CA282041"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["CA230223"],"award-info":[{"award-number":["CA230223"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-192048"],"award-info":[{"award-number":["PJT-192048"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","award":["1258936"],"award-info":[{"award-number":["1258936"]}],"id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003287","name":"Rally Foundation","doi-asserted-by":"publisher","award":["24YIN30"],"award-info":[{"award-number":["24YIN30"]}],"id":[{"id":"10.13039\/100003287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","award":["663113"],"award-info":[{"award-number":["663113"]}],"id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015803","name":"BC Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Gene fusions generated by chromosomal rearrangements function as oncogenic drivers in human cancers. We previously showed that EWSR1\u2013ETS oncofusions of Ewing sarcoma directly induce surface expression of IL1 receptor accessory protein (IL1RAP), which along with limited expression in healthy tissues except in the placenta nominate IL1RAP as a promising Ewing sarcoma immunotherapy target. We therefore engineered antibody\u2013drug conjugates (ADC) with different cytotoxic payloads to target IL1RAP. ADCs potently blocked tumor growth and induced durable regression of Ewing sarcoma xenografts in mice and diminished metastatic dissemination in vivo. Moreover, we show that other oncofusions also induce IL1RAP expression in diverse cancers, including NPM\u2013ALK in anaplastic large cell lymphoma and ETV6\u2013NTRK3 in multiple tumor types. IL1RAP expression rendered these malignancies similarly vulnerable to IL1RAP-targeting ADCs, which effectively blocked the growth of ALCL xenografts and syngeneic ETV6\u2212NTRK3+ sarcomas. Lack of detectable normal tissue toxicity, including in nonhuman primates, supports the further clinical translation of IL1RAP-targeting ADCs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The IL1RAP surface protein is induced by multiple oncogenic fusions, including EWSR1\u2013ETS, NPM\u2013ALK, and EN in distinct malignancies, rendering these cancers vulnerable to anti-IL1RAP ADCs. We demonstrate that IL1RAP-targeting ADCs have potent efficacy in both primary and metastatic diseases and are well tolerated in nonhuman primates, warranting their further clinical translation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-25-1036","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:49:12Z","timestamp":1776091752000},"page":"1859-1883","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["IL1RAP Antibody\u2013Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8215-1870","authenticated-orcid":false,"given":"Hai-Feng","family":"Zhang","sequence":"first","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada."},{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 2 Department of Molecular Oncology, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6941-889X","authenticated-orcid":false,"given":"Edouard","family":"De Dreuzy","sequence":"additional","affiliation":[{"name":"3Advesya Therapeutics, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3381-9640","authenticated-orcid":false,"given":"Yue Zhou","family":"Huang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 2 Department of Molecular Oncology, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3014-502X","authenticated-orcid":false,"given":"Seungmin","family":"Shin","sequence":"additional","affiliation":[{"name":"4Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1594-8884","authenticated-orcid":false,"given":"Qing-Feng","family":"Huang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02gxych78","id-type":"ROR","asserted-by":"publisher"}],"name":"Shantou University Medical College 5 Department of Pathology, Second Affiliated Hospital, , Shantou, China."},{"id":[{"id":"https:\/\/ror.org\/02gxych78","id-type":"ROR","asserted-by":"publisher"}],"name":"Shantou University Medical College 6 Institute of Oncologic Pathology, , Shantou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7416-6503","authenticated-orcid":false,"given":"Alberto","family":"Delaidelli","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 2 Department of Molecular Oncology, , Vancouver, Canada."},{"name":"7Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6106-3201","authenticated-orcid":false,"given":"Xiaqiu","family":"Yang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 2 Department of Molecular Oncology, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9783-9163","authenticated-orcid":false,"given":"Virginia","family":"Adamiak","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 2 Department of Molecular Oncology, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9979-3690","authenticated-orcid":false,"given":"Andrew","family":"Lytle","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada."},{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 8 Centre for Lymphoid Cancer and Department of Medical Oncology, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5876-6604","authenticated-orcid":false,"given":"Aarzoo","family":"Arzoo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 2 Department of Molecular Oncology, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3981-0978","authenticated-orcid":false,"given":"Michael M.","family":"Lizardo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 2 Department of Molecular Oncology, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9773-8465","authenticated-orcid":false,"given":"Qiaochu","family":"Lin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 2 Department of Molecular Oncology, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9923-9961","authenticated-orcid":false,"given":"Shreya","family":"Sanadi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 2 Department of Molecular Oncology, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4154-3127","authenticated-orcid":false,"given":"Melanie","family":"Rouleau","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 2 Department of Molecular Oncology, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9747-8657","authenticated-orcid":false,"given":"Lu-Xin","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02gxych78","id-type":"ROR","asserted-by":"publisher"}],"name":"Shantou University Medical College 5 Department of Pathology, Second Affiliated Hospital, , Shantou, China."},{"id":[{"id":"https:\/\/ror.org\/02gxych78","id-type":"ROR","asserted-by":"publisher"}],"name":"Shantou University Medical College 6 Institute of Oncologic Pathology, , Shantou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1618-4292","authenticated-orcid":false,"given":"Li-Yan","family":"Xu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02gxych78","id-type":"ROR","asserted-by":"publisher"}],"name":"Shantou University Medical College 5 Department of Pathology, Second Affiliated Hospital, , Shantou, China."},{"id":[{"id":"https:\/\/ror.org\/02gxych78","id-type":"ROR","asserted-by":"publisher"}],"name":"Shantou University Medical College 6 Institute of Oncologic Pathology, , Shantou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6375-3614","authenticated-orcid":false,"given":"En-Min","family":"Li","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02gxych78","id-type":"ROR","asserted-by":"publisher"}],"name":"Shantou University Medical College 5 Department of Pathology, Second Affiliated Hospital, , Shantou, China."},{"id":[{"id":"https:\/\/ror.org\/02gxych78","id-type":"ROR","asserted-by":"publisher"}],"name":"Shantou University Medical College 9 The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Department of Biochemistry and Molecular Biology, , Shantou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-2407","authenticated-orcid":false,"given":"Raymond","family":"Lai","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0160cpw27","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Alberta 10 Department of Laboratory Medicine and Pathology, , Edmonton, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4522-6163","authenticated-orcid":false,"given":"Cl\u00e9mentine","family":"Primus","sequence":"additional","affiliation":[{"name":"3Advesya Therapeutics, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0016-979X","authenticated-orcid":false,"given":"Soha","family":"Reda El Sayed","sequence":"additional","affiliation":[{"name":"3Advesya Therapeutics, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7688-8387","authenticated-orcid":false,"given":"Lucas","family":"Bourhis","sequence":"additional","affiliation":[{"name":"3Advesya Therapeutics, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8402-0430","authenticated-orcid":false,"given":"Delphine","family":"Genin","sequence":"additional","affiliation":[{"name":"3Advesya Therapeutics, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5656-0423","authenticated-orcid":false,"given":"Lucas","family":"Demontrond","sequence":"additional","affiliation":[{"name":"3Advesya Therapeutics, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3063-2548","authenticated-orcid":false,"given":"Lucie","family":"Bouquet","sequence":"additional","affiliation":[{"name":"3Advesya Therapeutics, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1310-4979","authenticated-orcid":false,"given":"Laura","family":"Labarthe D\u00e9molis","sequence":"additional","affiliation":[{"name":"3Advesya Therapeutics, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2024-3495","authenticated-orcid":false,"given":"Amandine","family":"Barberot","sequence":"additional","affiliation":[{"name":"3Advesya Therapeutics, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0158-9840","authenticated-orcid":false,"given":"Stephane","family":"Lameynardie","sequence":"additional","affiliation":[{"name":"3Advesya Therapeutics, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3308-4549","authenticated-orcid":false,"given":"Alexis","family":"Delabri\u00e8re","sequence":"additional","affiliation":[{"name":"3Advesya Therapeutics, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6714-0708","authenticated-orcid":false,"given":"Haiqing","family":"Hua","sequence":"additional","affiliation":[{"name":"11DualityBio, Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0402-2674","authenticated-orcid":false,"given":"Junjie","family":"Yang","sequence":"additional","affiliation":[{"name":"11DualityBio, Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3418-0922","authenticated-orcid":false,"given":"Rieko","family":"Ishima","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01an3r305","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pittsburgh 12 Department of Structural Biology, School of Medicine, , Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-6952","authenticated-orcid":false,"given":"Roland","family":"Imle","sequence":"additional","affiliation":[{"name":"13Hopp Children\u2019s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-0003","authenticated-orcid":false,"given":"Ana","family":"Banito","sequence":"additional","affiliation":[{"name":"13Hopp Children\u2019s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9132-3611","authenticated-orcid":false,"given":"Graham W.","family":"Slack","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 8 Centre for Lymphoid Cancer and Department of Medical Oncology, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9863","authenticated-orcid":false,"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 8 Centre for Lymphoid Cancer and Department of Medical Oncology, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8088-7929","authenticated-orcid":false,"given":"John M.","family":"Maris","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01z7r7q48","id-type":"ROR","asserted-by":"publisher"}],"name":"Children\u2019s Hospital of Philadelphia 14 Division of Oncology and Center for Childhood Cancer Research, , Philadelphia, Pennsylvania."},{"name":"15Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1424-2858","authenticated-orcid":false,"given":"Kristopher R.","family":"Bosse","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01z7r7q48","id-type":"ROR","asserted-by":"publisher"}],"name":"Children\u2019s Hospital of Philadelphia 14 Division of Oncology and Center for Childhood Cancer Research, , Philadelphia, Pennsylvania."},{"name":"15Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2258-1024","authenticated-orcid":false,"given":"Dimiter S.","family":"Dimitrov","sequence":"additional","affiliation":[{"name":"4Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-9750","authenticated-orcid":false,"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada."},{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 8 Centre for Lymphoid Cancer and Department of Medical Oncology, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6960-7404","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"4Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5407-9787","authenticated-orcid":false,"given":"Richard C.A.","family":"Sainson","sequence":"additional","affiliation":[{"name":"3Advesya Therapeutics, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7447-2199","authenticated-orcid":false,"given":"Poul H.","family":"Sorensen","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada."},{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer Agency 2 Department of Molecular Oncology, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"2026090103071976200_bib1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090103071976200_bib2","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"key":"2026090103071976200_bib3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"2026090103071976200_bib4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026090103071976200_bib5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S1470-2045(19)30777-6","article-title":"Immune checkpoint inhibitors for refractory childhood cancers","volume":"21","author":"Widemann","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026090103071976200_bib6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026090103071976200_bib7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2026090103071976200_bib8","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"key":"2026090103071976200_bib9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/abt\/tbaf010","article-title":"A review of conjugation technologies for antibody drug conjugates","volume":"8","author":"Fan","year":"2025","journal-title":"Antib Ther"},{"key":"2026090103071976200_bib10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","article-title":"Ewing sarcoma","volume":"4","author":"Gr\u00fcnewald","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026090103071976200_bib11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMra2028910","article-title":"Ewing\u2019s sarcoma","volume":"384","author":"Riggi","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090103071976200_bib12","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.3390\/jcm10081685","article-title":"Ewing sarcoma-diagnosis, treatment, clinical challenges and future perspectives","volume":"10","author":"Z\u00f6llner","year":"2021","journal-title":"J Clin Med"},{"key":"2026090103071976200_bib13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.humpath.2024.01.007","article-title":"Updates on WHO classification for small round cell tumors: Ewing sarcoma vs. everything else","volume":"147","author":"Dehner","year":"2024","journal-title":"Hum Pathol"},{"key":"2026090103071976200_bib14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"2026090103071976200_bib15","doi-asserted-by":"publisher","first-page":"e000653","DOI":"10.1136\/jitc-2020-000653","article-title":"Role of immunotherapy in Ewing sarcoma","volume":"8","author":"Morales","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026090103071976200_bib16","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1158\/2159-8290.CD-20-1690","article-title":"Proteomic screens for suppressors of anoikis identify IL1RAP as a promising surface target in Ewing sarcoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Cancer Discov"},{"key":"2026090103071976200_bib17","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41556-024-01425-8","article-title":"Exploiting ferroptosis vulnerabilities in cancer","volume":"26","author":"Nakamura","year":"2024","journal-title":"Nat Cell Biol"},{"key":"2026090103071976200_bib18","doi-asserted-by":"publisher","first-page":"14918","DOI":"10.3390\/ijms232314918","article-title":"IL-1RAP, a key therapeutic target in cancer","volume":"23","author":"Frenay","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026090103071976200_bib19","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1084\/jem.20180147","article-title":"IL1RAP potentiates multiple oncogenic signaling pathways in AML","volume":"215","author":"Mitchell","year":"2018","journal-title":"J Exp Med"},{"key":"2026090103071976200_bib20","doi-asserted-by":"publisher","first-page":"10786","DOI":"10.1073\/pnas.1422749112","article-title":"Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia","volume":"112","author":"\u00c5gerstam","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026090103071976200_bib21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-024-01586-x","article-title":"IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2026090103071976200_bib22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13045-025-01755-6","article-title":"MicroRNA-142 improves IL1RAP CAR-T cell activity in acute myeloid leukemia","volume":"18","author":"Harada","year":"2025","journal-title":"J Hematol Oncol"},{"key":"2026090103071976200_bib23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1158\/0008-5472.CAN-18-1078","article-title":"CML hematopoietic stem cells expressing IL1RAP can Be targeted by chimeric antigen receptor-engineered T cells","volume":"79","author":"Warda","year":"2019","journal-title":"Cancer Res"},{"key":"2026090103071976200_bib24","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1182\/blood-2015-11-679985","article-title":"IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models","volume":"128","author":"\u00c5gerstam","year":"2016","journal-title":"Blood"},{"key":"2026090103071976200_bib25","doi-asserted-by":"publisher","first-page":"e009523","DOI":"10.1136\/jitc-2024-009523","article-title":"Blocking IL1RAP on cancer-associated fibroblasts in pancreatic ductal adenocarcinoma suppresses IL-1-induced neutrophil recruitment","volume":"12","author":"Hansen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026090103071976200_bib26","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.1158\/1078-0432.CCR-24-0645","article-title":"Efficacy and safety of the anti-IL1RAP antibody nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in patients with advanced\/metastatic pancreatic cancer","volume":"30","author":"Van Cutsem","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026090103071976200_bib27","doi-asserted-by":"publisher","first-page":"153141","DOI":"10.1016\/j.prp.2020.153141","article-title":"IL1RAP regulated by PRPRD promotes gliomas progression via inducing neuronal synapse development and neuron differentiation in vitro","volume":"216","author":"Li","year":"2020","journal-title":"Pathol Res Pract"},{"key":"2026090103071976200_bib28","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1158\/2159-8290.CD-25-0382","article-title":"HPV16-Expressing tumors release multiple IL1 ligands to orchestrate systemic immunosuppression whose disruption enables efficacy of a therapeutic vaccine","volume":"15","author":"Lecointre","year":"2025","journal-title":"Cancer Discov"},{"issue":"Suppl 2","key":"2026090103071976200_bib29","doi-asserted-by":"publisher","first-page":"A1234","DOI":"10.1136\/jitc-2022-SITC2022.1192","article-title":"1192 Identification of oncogene-induced surface protein IL1RAP as an immunotherapy target in multiple cancers","volume":"10","author":"Zhang","year":"2022","journal-title":"J ImmunoTherapy Cancer"},{"issue":"8_Suppl_1","key":"2026090103071976200_bib30","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1158\/1538-7445.AM2025-4260","article-title":"ADV-101: a novel ADC targeting IL-1RAP, leveraging tumor cell and the tumor microenvironment vulnerabilities for enhanced anti-tumor efficacy","volume":"85","author":"De Dreuzy","year":"2025","journal-title":"Cancer Res"},{"issue":"8_Suppl_1","key":"2026090103071976200_bib31","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1158\/1538-7445.AM2025-2875","article-title":"IL1RAP-targeting antibody-drug conjugate: a novel therapeutic targeting both tumor cells and the tumor microenvironment","volume":"85","author":"Gyllenback","year":"2025","journal-title":"Cancer Res"},{"issue":"8_Suppl_1","key":"2026090103071976200_bib32","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1158\/1538-7445.AM2025-4253","article-title":"Turning pro-tumor inflammation into target opportunity: development of an IL1RAP ADC for solid tumor treatment","volume":"85","author":"Chen","year":"2025","journal-title":"Cancer res"},{"key":"2026090103071976200_bib33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrc2091","article-title":"The impact of translocations and gene fusions on cancer causation","volume":"7","author":"Mitelman","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2026090103071976200_bib34","doi-asserted-by":"publisher","first-page":"oyae126","DOI":"10.1093\/oncolo\/oyae126","article-title":"Oncofusions - shaping cancer care","volume":"30","author":"Dashi","year":"2025","journal-title":"Oncologist"},{"key":"2026090103071976200_bib35","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"2026090103071976200_bib36","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41591-019-0542-z","article-title":"Resistance to TRK inhibition mediated by convergent MAPK pathway activation","volume":"25","author":"Cocco","year":"2019","journal-title":"Nat Med"},{"key":"2026090103071976200_bib37","doi-asserted-by":"publisher","first-page":"104234","DOI":"10.1016\/j.critrevonc.2023.104234","article-title":"Oncogenic fusions: targeting NTRK","volume":"194","author":"Hagopian","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl 3","key":"2026090103071976200_bib38","doi-asserted-by":"publisher","first-page":"iii42","DOI":"10.1093\/annonc\/mdw305","article-title":"Crizotinib resistance: implications for therapeutic strategies","volume":"27","author":"Dagogo-Jack","year":"2016","journal-title":"Ann Oncol"},{"key":"2026090103071976200_bib39","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026090103071976200_bib40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood.2021014663","article-title":"The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma","volume":"140","author":"Calabretta","year":"2022","journal-title":"Blood"},{"key":"2026090103071976200_bib41","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4 Suppl","key":"2026090103071976200_bib42","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/cncr.24790","article-title":"Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model","volume":"116","author":"Nilsson","year":"2010","journal-title":"Cancer"},{"key":"2026090103071976200_bib43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cell.2020.09.007","article-title":"High potency of a bivalent human VH domain in SARS-CoV-2 animal models","volume":"183","author":"Li","year":"2020","journal-title":"Cell"},{"key":"2026090103071976200_bib44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/s12951-022-01648-7","article-title":"In vivo fluorescence imaging: success in preclinical imaging paves the way for clinical applications","volume":"20","author":"Refaat","year":"2022","journal-title":"J Nanobiotechnology"},{"issue":"9","key":"2026090103071976200_bib45","doi-asserted-by":"publisher","first-page":"094805","DOI":"10.1117\/1.JBO.28.9.094805","article-title":"Minimizing near-infrared autofluorescence in preclinical imaging with diet and wavelength selection","volume":"28","author":"Sun","year":"2023","journal-title":"J Biomed Opt"},{"key":"2026090103071976200_bib46","doi-asserted-by":"publisher","first-page":"eabq7866","DOI":"10.1126\/sciadv.abq7866","article-title":"A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo","volume":"9","author":"Guo","year":"2023","journal-title":"Sci Adv"},{"key":"2026090103071976200_bib47","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/biolre\/ioad134","article-title":"Ovarian follicle size or growth rate can both be determinants of ovulatory follicle selection in mice","volume":"110","author":"Richard","year":"2024","journal-title":"Biol Reprod"},{"key":"2026090103071976200_bib48","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1523\/JNEUROSCI.4637-11.2012","article-title":"Interleukin-1 receptor accessory protein organizes neuronal synaptogenesis as a cell adhesion molecule","volume":"32","author":"Yoshida","year":"2012","journal-title":"J Neurosci"},{"issue":"16 Supplement","key":"2026090103071976200_bib49","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1200\/jco.2025.43.16_suppl.5015","article-title":"DB-1311\/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC)","volume":"43","author":"Parsonson","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026090103071976200_bib50","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jaad.2024.08.036","article-title":"Dermatologic toxicities of antibody-drug conjugates","volume":"91","author":"Gronbeck","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026090103071976200_bib51","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"2026090103071976200_bib52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","article-title":"The biology and management of systemic anaplastic large cell lymphoma","volume":"126","author":"Hapgood","year":"2015","journal-title":"Blood"},{"key":"2026090103071976200_bib53","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/leu.2016.292","article-title":"NPM-ALK expression levels identify two distinct subtypes of paediatric anaplastic large cell lymphoma","volume":"31","author":"Pomari","year":"2017","journal-title":"Leukemia"},{"key":"2026090103071976200_bib54","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma","volume":"27","author":"Crescenzo","year":"2015","journal-title":"Cancer Cell"},{"key":"2026090103071976200_bib55","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026090103071976200_bib56","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"2026090103071976200_bib57","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/ng0298-184","article-title":"A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma","volume":"18","author":"Knezevich","year":"1998","journal-title":"Nat Genet"},{"key":"2026090103071976200_bib58","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/s1535-6108(02)00180-0","article-title":"Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma","volume":"2","author":"Tognon","year":"2002","journal-title":"Cancer Cell"},{"key":"2026090103071976200_bib59","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ccr.2007.11.012","article-title":"ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex","volume":"12","author":"Li","year":"2007","journal-title":"Cancer Cell"},{"key":"2026090103071976200_bib60","doi-asserted-by":"publisher","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"2026090103071976200_bib61","doi-asserted-by":"publisher","first-page":"103893","DOI":"10.1016\/j.amsu.2022.103893","article-title":"A review of NTRK fusions in cancer","volume":"79","author":"Manea","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"2026090103071976200_bib62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/path.5053","article-title":"Transcriptomic definition of molecular subgroups of small round cell sarcomas","volume":"245","author":"Watson","year":"2018","journal-title":"J Pathol"},{"key":"2026090103071976200_bib63","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.1038\/s41467-025-60519-5","article-title":"Somatic gene delivery faithfully recapitulates a molecular spectrum of high-risk sarcomas","volume":"16","author":"Imle","year":"2025","journal-title":"Nat Commun"},{"key":"2026090103071976200_bib64","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026090103071976200_bib65","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1084\/jem.20161645","article-title":"Inflammatory signals from photoreceptor modulate pathological retinal angiogenesis via c-Fos","volume":"214","author":"Sun","year":"2017","journal-title":"J Exp Med"},{"key":"2026090103071976200_bib66","doi-asserted-by":"publisher","first-page":"E2048","DOI":"10.1073\/pnas.1415111112","article-title":"Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-\u03b2 signaling","volume":"112","author":"Oruqaj","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026090103071976200_bib67","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1128\/MCB.23.8.2871-2882.2003","article-title":"c-Jun NH(2)-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor","volume":"23","author":"Ventura","year":"2003","journal-title":"Mol Cell Biol"},{"key":"2026090103071976200_bib68","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2026090103071976200_bib69","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"2026090103071976200_bib70","doi-asserted-by":"publisher","first-page":"e000548","DOI":"10.1136\/esmoopen-2019-000548","article-title":"From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer","volume":"4","author":"Pirker","year":"2019","journal-title":"ESMO Open"},{"key":"2026090103071976200_bib71","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090103071976200_bib72","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026090103071976200_bib73","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"2026090103071976200_bib74","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nrc1209","article-title":"AP-1: a double-edged sword in tumorigenesis","volume":"3","author":"Eferl","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2026090103071976200_bib75","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1038\/s41467-023-39953-w","article-title":"IL1R1+ cancer-associated fibroblasts drive tumor development and immunosuppression in colorectal cancer","volume":"14","author":"Koncina","year":"2023","journal-title":"Nat Commun"},{"key":"2026090103071976200_bib76","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2026090103071976200_bib77","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1182\/blood.2021012811","article-title":"Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma","volume":"139","author":"Sakemura","year":"2022","journal-title":"Blood"},{"key":"2026090103071976200_bib78","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1158\/2159-8290.CD-24-0131","article-title":"Cancer-associated fibroblasts serve as decoys to suppress NK cell anticancer cytotoxicity in breast cancer","volume":"15","author":"Ben-Shmuel","year":"2025","journal-title":"Cancer Discov"},{"key":"2026090103071976200_bib79","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s43018-021-00181-0","article-title":"Emerging strategies for treating metastasis","volume":"2","author":"Esposito","year":"2021","journal-title":"Nat Cancer"},{"key":"2026090103071976200_bib80","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/jnci\/85.21.1725","article-title":"Xenograft model of progressive human proliferative breast disease","volume":"85","author":"Miller","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2026090103071976200_bib81","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1089\/hum.2018.111","article-title":"Evaluating nonintegrating lentiviruses as safe vectors for noninvasive reporter-based molecular imaging of multipotent mesenchymal stem cells","volume":"29","author":"Hamilton","year":"2018","journal-title":"Hum Gene Ther"},{"key":"2026090103071976200_bib82","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1158\/2326-6066.CIR-23-0440","article-title":"Engagement of CD99 activates distinct programs in Ewing sarcoma and macrophages","volume":"12","author":"Manara","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"2026090103071976200_bib83","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/2472555219897567","article-title":"New advances in cell microarray technology to expand applications in target deconvolution and off-target screening","volume":"25","author":"Freeth","year":"2020","journal-title":"SLAS Discov"},{"key":"2026090103071976200_bib84","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1101\/gr.260851.120","article-title":"Interpretation of allele-specific chromatin accessibility using cell state-aware deep learning","volume":"31","author":"Atak","year":"2021","journal-title":"Genome Res"},{"key":"2026090103071976200_bib85","doi-asserted-by":"publisher","first-page":"E1307","DOI":"10.1073\/pnas.1500536112","article-title":"Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing","volume":"112","author":"Selvanathan","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026090103071976200_bib86","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.exphem.2018.09.004","article-title":"The Human Cell Atlas bone marrow single-cell interactive web portal","volume":"68","author":"Hay","year":"2018","journal-title":"Exp Hematol"},{"key":"2026090103071976200_bib87","doi-asserted-by":"publisher","first-page":"W45","DOI":"10.1093\/nar\/gkae358","article-title":"ChIP-Atlas 3.0: a data-mining suite to explore chromosome architecture together with large-scale regulome data","volume":"52","author":"Zou","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2026090103071976200_bib88","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41591-018-0262-9","article-title":"Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma","volume":"25","author":"Menotti","year":"2019","journal-title":"Nat Med"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-25-1036\/3767618\/cd-25-1036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-25-1036\/3821432\/cd-25-1036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/9\/1859\/3824594\/cd-25-1036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/9\/1859\/3824594\/cd-25-1036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:08:04Z","timestamp":1788246484000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/9\/1859\/787681\/IL1RAP-Antibody-Drug-Conjugates-Potently-Target"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":88,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,4,13]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-25-1036","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]}}}